John Garner

PLGA from PolySciTech used for nanoparticle based docetaxel delivery system

Blog Post created by John Garner on Jan 4, 2016

PolySciTech Division of Akina, Inc ( provides a wide array of biodegradable polymers including PLGA. Recently, PLGA (Cat# AP082) from PolySciTech was used, along with HS15 nonionic surfactant to generate nanoparticles loaded with docetaxel. These nanoparticles (~169 nm in size, about 250 times smaller than a typical 40 um human tissue cell) possessed good drug distribution throughout and other properties which indicated that they would have good capabilities for drug delivery. Read more: Cho, Hyun-Jong, Ju-Hwan Park, Dae-Duk Kim, and In-Soo Yoon. "Poly (lactic-co-glycolic) Acid/Solutol HS15-Based Nanoparticles for Docetaxel Delivery." Journal of Nanoscience and Nanotechnology 16, no. 2 (2016): 1433-1436.


  “Abstract:Docetaxel (DCT) is one of anti-mitotic chemotherapeutic agents and has been used for the treatment of gastric cancer as well as head and neck cancer, breast cancer and prostate cancer. Poly(lacticco-glycolic) acid (PLGA) is one of representative biocompatible and biodegradable polymers, and polyoxyl 15 hydroxystearate (Solutol HS15) is a nonionic solubilizer and emulsifying agent. In this investigation, PLGA/Solutol HS15-based nanoparticles (NPs) for DCT delivery were fabricated by a modified emulsification-solvent evaporation method. PLGA/Solutol HS15/DCT NPs with about 169 nm of mean diameter, narrow size distribution, negative zeta potential, and spherical morphology were prepared. The results of solid-state studies revealed the successful dispersion of DCT in PLGA matrix and its amorphization during the preparation process of NPs. According to the result of in vitro release test, emulsifying property of Solutol HS15 seemed to contribute to the enhanced drug release from NPs at physiological pH. All these findings imply that developed PLGA/Solutol HS15-based NP can be a promising local anticancer drug delivery system for cancer therapy.”